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vitamin B12 deficiency is common in pediatric leukemia 
patients.
Conclusions Use of nitrous oxide in pediatric leukemia 
patients at the same time as methotrexate use should be 
avoided especially as many suitable alternative anesthetic 
agents exist. Clinicians should consider monitoring levels 
of vitamin B12 in patients suspected of having methotrex-
ate-induced neurotoxic effects.
Keywords Neurotoxicity · Hematology · Methotrexate · 
Nitrous oxide · Leukemia · Toxicity
Adverse neurological events are very common during treat-
ment for pediatric acute lymphoblastic leukemia (ALL) and 
include seizures, stroke-like syndrome and leukoencepha-
lopathy. Recent trials report neurological adverse events in 
4–20 % of patients [1, 2]. Additionally, chronic neurotoxic-
ity is emerging as a worrying late effect [3], and 40–60 % 
of childhood ALL survivors experience neurocognitive dif-
ficulties [4], with methotrexate strongly implicated. Despite 
toxicities, this mainstay of ALL therapy, given intrave-
nously, orally and intrathecally (IT) is credited with driv-
ing down the incidence of central nervous system (CNS) 
relapse without the need for radiotherapy.
Additionally, although rare, neurotoxicity with similar 
radiological features of leukoencephalopathy has occa-
sionally been reported following oral methotrexate used in 
patients with autoimmune and inflammatory disorders [5, 
6], where neurotoxicity may appear many years into treat-
ment in patients on a stable dose of methotrexate. Genome 
wide association studies in childhood ALL patients have 
failed to conclusively identify any predictive genetic mark-
ers for methotrexate neurotoxicity [7]. Neurotoxicity is not 
directly dose related and does not necessarily occur on first 
Abstract 
Purpose Methotrexate administration is associated with 
frequent adverse neurological events during treatment for 
childhood acute lymphoblastic leukemia. Here, we present 
evidence to support the role of common drug interactions 
and low vitamin B12 levels in potentiating methotrexate 
neurotoxicity.
Methods We review the published evidence and highlight 
key potential drug interactions as well as present clinical 
evidence of severe methotrexate neurotoxicity in conjunc-
tion with nitrous oxide anesthesia and measurements of 
vitamin B12 levels among pediatric leukemia patients dur-
ing therapy.
Results We describe a very plausible mechanism for 
methotrexate neurotoxicity in pediatric leukemia patients 
involving reduction in methionine and consequential dis-
ruption of myelin production. We provide evidence that a 
number of commonly prescribed drugs in pediatric leuke-
mia management interact with the same folate biosynthetic 
pathways and/or reduce functional vitamin B12 levels and 
hence are likely to increase the toxicity of methotrexate in 
these patients. We also present a brief case study support-
ing out hypothesis that nitrous oxide contributes to metho-
trexate neurotoxicity and a nutritional study, showing that 
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exposure or on re-exposure after a neurological event [8] as 
may be expected if attributed to genetic vulnerability. This 
suggests that additional risk factors may be important.
We propose that methotrexate-induced neurotoxicity 
may be potentiated by common drug interactions, and/or 
the presence of low vitamin B12 (cobalamin) levels, which 
lead to elevated methotrexate levels in cerebrospinal fluid 
(CSF) or result in synergistic or additive effects on con-
vergent metabolic pathways. A particularly important and 
under-appreciated drug interaction may be the concomi-
tant use of inhaled nitrous oxide (N2O) and methotrexate, 
which is common practice in many pediatric hematology 
centers where lumbar punctures to administer intrathecal 
(IT) methotrexate are performed under general anesthesia.
A recent case report highlighted the risk of severe neu-
rotoxicity with the combination of N2O and methotrex-
ate [9]. Here, we briefly present a second case with mul-
tiple acquired risk factors. A 12-year-old girl with acute 
undifferentiated leukemia received regular IT methotrex-
ate as part of her chemotherapy schedule. All IT therapy 
was administered under general anesthesia with propofol 
induction followed by a gaseous mix of N2O and oxygen. 
Other concomitant drugs included the proton-pump inhibi-
tor (PPI) omeprazole. Four days after the 5th dose of IT 
methotrexate, she was presented with focal seizures rapidly 
progressing to generalized tonic–clonic seizures, disinhibi-
tion, severe agitation and left upper limb (LUL) weakness. 
MRI (T2/FLAIR and diffusion weighted) imaging on day 
2 showed widespread hyperintense subcortical white mat-
ter lesions in the frontal and parietal regions with areas of 
restricted diffusion consistent with leukoencephalopathy. 
Seizure activity continued for 5 days despite maximal anti-
convulsant doses of benzodiazapines and levetiracetam and 
the radiological changes worsened with increasing cerebral 
edema and pressure effects requiring dexamethasone. She 
made a clinical recovery over the next 7 days but with some 
residual LUL weakness. Serum vitamin B12 was measured 
on recovery (3 weeks from the last IT methotrexate) and 
was low at 154 ng/L (normal range 200–1100 ng/L).
Methotrexate exerts its anti-leukemic action via inhi-
bition of the enzyme dihydrofolate reductase, ultimately 
reducing the amount of tetrahydrofolate available for DNA 
synthesis leading to cell death (summarized in Fig. 1). The 
reduction in tetrahydrofolate also results in reduced synthe-
sis of methionine from the precursor homocysteine by the 
enzyme methionine synthase, which requires vitamin B12 
as a co-factor. Methionine is then converted to S-adenosyl 
methionine (SAM), a methyl donor which has a critical role 
in regulating myelin sheath formation and lipid production 
[10]. This combined with known neuroexcitatory proper-
ties of downstream products of homocysteine [11] (Fig. 1) 
may explain the propensity for CNS side effects in these 
patients. Indeed, CSF concentrations of SAM were found 
to be significantly lower in pediatric leukemia patients dur-
ing methotrexate treatment compared to age-matched con-
trols, whereas levels of myelin basic protein, considered to 
be a marker of myelin breakdown, were increased [12].
Methionine depletion and accumulation of homocyst-
eine may be potentiated by the co-administration of other 
medications via two mechanisms; (1) a direct drug interac-
tion leading to increased methotrexate plasma (and/or CSF) 
concentrations or (2) interference with the same metabolic 
pathways as methotrexate. Examples of (1) include fluo-
roquinolone antibiotics, piperacillin (the most commonly 
prescribed antibiotic for episodes of febrile neutropenia 
during pediatric leukemia treatment in the UK) and proton-
pump inhibitors (PPIs). The latter delay plasma elimination 
of methotrexate leading to renal and liver toxicity [13]. A 
number of drugs interfere with (2), mainly via depletion of 
functional vitamin B12 (Fig. 1)—as exemplified by nitrous 
oxide [14]. In addition, PPIs may reduce the bioavailabil-
ity of dietary vitamin B12 [15] and antimetabolites such as 
6-mercaptopurine may cause B12 malabsorption secondary 
to enteropathy. Indeed, a small pilot study in our local insti-
tution recorded low vitamin B12 levels during treatment in 
4/19 pediatric patients (21 %) with ALL. Three out of four 
patients where levels were low experienced severe gastro-
intestinal enteropathy and 1 patient experienced a severe 
neurological event. In addition, the same study revealed 
that 9/17 of the same cohort tested for zinc had clinically 
low levels at some point during their treatment. Zinc is also 
a critical co-factor for methionine synthase (Fig. 1); hence, 
low levels may also contribute to the disruption of this 
pathway by methotrexate treatment.
The evidence presented above suggests that low B12 
levels, recent general anesthesia with nitrous oxide or 
introduction of additional drugs interacting with the same 
pathways, may be responsible for the idiosyncratic occur-
rence of methotrexate neurotoxicity in pediatric leukemia 
patients undergoing treatment with high doses. We aim to 
raise awareness globally of this potential interaction and 
particularly ensure that nitrous oxide anesthesia is avoided 
in all patients on methotrexate as advised by the British 
National Formulary [16].
In the era where personalized medicine integrated 
with genomic approaches is seen as the ultimate goal, it 
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is important not to overlook ‘old-fashioned’ drug interac-
tions, especially if such risks can easily be minimized by 
a change in drug scheduling or use of suitable alternative 
agents.
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Fig. 1  A summary of the biochemical reactions involving folate and 
vitamin B12 inside an oligodendrocyte and proposed inhibition of 
myelin production by co-administration of methotrexate (MTX) and 
drugs affecting vitamin B12. Abbreviations: 5-MTHF (5-methyltet-
rahydrofolate, levomefolic acid), MB12 (methyl B12), THF (tetrahy-
drofolate, tetrahydrofolic acid), 5,10-MTHF (5,10-methylene THF), 
DHF (dihydrofolate, dihydrofolic acid), DHFR (dihydrofolate reduc-
tase), MB12 (methyl-vitamin B12), MTHFR (methylenetetrafolate 
reductase), MTX (methotrexate), met synthase (methionine synthase), 
SHMT (serine hydroxyl-methyltransferase). MTHF participates in 
the production of methionine from homocysteine by methionine syn-
thase, catalyzed by MB12 and zinc, creating THF and methionine. 
THF participates in the production of purines and pyrimidines for 
DNA synthesis. Methionine is a vital amino acid involved in mye-
lin production via its conversion to S-adenosyl methionine (SAM). 
SAM is involved in the methylation of many proteins and interme-
diates ultimately involved in myelin production, such as phosphati-
dylcholine, which is important in the production of sphingomyelin, 
a major component of the myelin sheath. Homocysteine can be con-
verted to homocysteic acid and homocysteine sulfinic acid which are 
excitotoxic glutamate analogues acting at the N-methyl-d-aspartate 
(NMDA) receptor, which may be a factor in acute methotrexate-
induced neurotoxicity. Methotrexate inhibits the function of DHFR, 
preventing the conversion of DHF to MTHF. Active vitamin B12 con-
tains reduced cobalt (Co+), but nitrous oxide (N2O) produces irre-
versible oxidation to Co++ and Co+++, rendering vitamin B12 inac-
tive. Any simultaneous compromise of folate and vitamin B12 via 
co-administration of methotrexate and agents known to deplete active 
vitamin B12, such as N2O could result in increased homocysteine and 
reduced methionine levels both of which may contribute to the neu-
rotoxic effects of methotrexate treatment. Other as yet unidentified 
compounds may also reduce bioavailable vitamin B12 levels. Blue 
arrows indicate proposed increase or reduction in various relevant 
pathway metabolites
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